CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Jun\u00edn virus, while also looking to improve manufacturing speed and scale-up of ChAdOx technology.\r\nLearnings could be leveraged to inform vaccine design for related viruses from the Arenavirus family, giving the world a head start in rapidly responding to future outbreaks in as little as 100 days.\r\nFirst project to be initiated under CEPI and University of Oxford\u2019s strategic partnership to accelerate global pandemic preparedness efforts.
This field school will offer methodological and theoretical training in multispecies ethnography and ecology - with a special focus on the cave ecosystems near Thai Buddhist temples.
An international group of maternal and child population health experts are calling on governments to invest in better obstetric surveillance systems, break down barriers in data sharing, and eradicate a culture of blame to help address stagnating maternal mortality rates globally.
An international consortium of multidisciplinary researchers and specialists has developed a new method to counter the problem of COVID-19 vaccine falsification
As the COVID-19 pandemic demonstrated, viruses can quickly evolve new ways of evading our immune systems, undermining our efforts to control outbreaks. But a new artificial intelligence (AI) tool developed by researchers at the University of Oxford and Harvard Medical School could help predict new viral variants before they emerge. The findings have been published in the journal Nature.
Professor Alan Bernstein has been appointed as the new head of Oxford Global Health, which will bring together and showcase the breadth of global health research across the University of Oxford.
Project headed by Oxford University\u2019s Professor Teresa Lambe OBE (Calleva Head of Vaccinology and Immunology, Department of Paediatrics) and co-developer of the Oxford/AstraZeneca COVID-19 vaccine and Paul Klenerman (Sidney Truelove Professor, Nuffield Department of Medicine)\r\n\u00a38 million funding from UKRI will catalyse global cooperation to improve understanding of existing COVID-19 vaccines and enhance future vaccine development\r\nThe research aims to enhance protection against several current and future respiratory pathogens \u2013 including COVID-19, flu and Respiratory Syncytial Virus (RSV) \u2013 contributing crucial new knowledge to future pandemic preparedness.
A breakthrough technique developed by University of Oxford researchers could one day provide tailored repairs for those who suffer brain injuries. The researchers demonstrated for the first time that neural cells can be 3D printed to mimic the architecture of the cerebral cortex. These results have been published in the journal Nature Communications.
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax\u2019s adjuvant is critical to reducing over half a million malaria-related deaths annually.
The University of Oxford\u2019s commitment to tackling major global health challenges has been strengthened following the endowment of a chair in global health and clinical development. The new permanent post was made possible by a \u00a35 million donation from Brazilian healthcare organisation SAIL for Health.
The UK trial is the next step in the development of a vaccine to protect people against MERS \u2013 a deadly viral illness with no current vaccines and the potential to cause a pandemic.
The MBRRACE-UK Collaboration, jointly led by Nuffield Department of Population Health\u2019s National Perinatal Epidemiology Unit (NPEU) and the University of Leicester\u2019s The Infant Mortality and Morbidity Studies (TIMMS) research group, has published a \u2018State of the Nation\u2019 report on perinatal deaths in babies born in the UK in 2021.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax\u2019s adjuvant technology, has been licensed for use in Burkina Faso by the country\u2019s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
A research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings, published today in the journal Nature Communications, could help develop more effective interventions to prevent AMR infections developing in vulnerable patients.
![\"Woman](\"https://www.globalhealth.ox.ac.uk/news/cepi-and-university-of-oxford-advance-vaccine-work-against-potentially-deadly-arenaviruses/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n